Vitiligo und Autoantikörper: Systematischer review und Metaanalyse

Translated title of the contribution: Vitiligo and autoantibodies: A systematic review and meta-analysis

Che Wei Liu, Yu-Chen Huang

Research output: Contribution to journalReview article

Abstract

Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1%, 9.7%, 12.5%, 11.7%, 12.6%, 0.2%, and 2.5%, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95%; confidence interval [CI]: 3.085–5.122), ATG antibodies (OR: 3.759; 95% CI: 2.554–5.531), ANA (OR: 1.797, 95% CI: 1.182–2.731), AGPCA (OR: 2.503; 95% CI: 1.497–2.896), and anti-adrenal antibodies (OR: 9.808, 95% CI: 1.809–53.159) (Figure 2a–e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.

Original languageGerman
Pages (from-to)845-853
Number of pages9
JournalJDDG - Journal of the German Society of Dermatology
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Vitiligo
Autoantibodies
Meta-Analysis
Anti-Idiotypic Antibodies
Odds Ratio
Confidence Intervals
Gastric Parietal Cells
Antinuclear Antibodies
Control Groups
Antibodies
Thyroid Diseases
Autoimmune Diseases
Smooth Muscle
Case-Control Studies
Thyroid Gland

ASJC Scopus subject areas

  • Dermatology

Cite this

Vitiligo und Autoantikörper : Systematischer review und Metaanalyse. / Liu, Che Wei; Huang, Yu-Chen.

In: JDDG - Journal of the German Society of Dermatology, Vol. 16, No. 7, 01.07.2018, p. 845-853.

Research output: Contribution to journalReview article

@article{321bb29f79024130b19db817e627b52d,
title = "Vitiligo und Autoantik{\"o}rper: Systematischer review und Metaanalyse",
abstract = "Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1{\%}, 9.7{\%}, 12.5{\%}, 11.7{\%}, 12.6{\%}, 0.2{\%}, and 2.5{\%}, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95{\%}; confidence interval [CI]: 3.085–5.122), ATG antibodies (OR: 3.759; 95{\%} CI: 2.554–5.531), ANA (OR: 1.797, 95{\%} CI: 1.182–2.731), AGPCA (OR: 2.503; 95{\%} CI: 1.497–2.896), and anti-adrenal antibodies (OR: 9.808, 95{\%} CI: 1.809–53.159) (Figure 2a–e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.",
author = "Liu, {Che Wei} and Yu-Chen Huang",
year = "2018",
month = "7",
day = "1",
doi = "10.1111/ddg.13574",
language = "德语",
volume = "16",
pages = "845--853",
journal = "JDDG - Journal of the German Society of Dermatology",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Vitiligo und Autoantikörper

T2 - Systematischer review und Metaanalyse

AU - Liu, Che Wei

AU - Huang, Yu-Chen

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1%, 9.7%, 12.5%, 11.7%, 12.6%, 0.2%, and 2.5%, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95%; confidence interval [CI]: 3.085–5.122), ATG antibodies (OR: 3.759; 95% CI: 2.554–5.531), ANA (OR: 1.797, 95% CI: 1.182–2.731), AGPCA (OR: 2.503; 95% CI: 1.497–2.896), and anti-adrenal antibodies (OR: 9.808, 95% CI: 1.809–53.159) (Figure 2a–e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.

AB - Many studies have reported the prevalence of autoantibodies in patients with vitiligo; however, results were inconsistent for some autoantibodies. This study aimed to conduct a systematic review and meta-analysis of the prevalence of autoantibodies in vitiligo patients. A systematic review and meta-analysis of the literature published from inception to Dec 31, 2016 was conducted. Case-control studies with vitiligo patients and a control group were included. The prevalence of anti-thyroperoxidase (ATPO) antibodies, anti-thyroglobulin (ATG) antibodies, antinuclear antibodies (ANA), anti-gastric parietal cell antibodies (AGPCA), anti-smooth muscle antibodies (ASMA), anti-mitochondrial antibodies (AMA), and anti-adrenal antibodies in vitiligo patients were 15.1%, 9.7%, 12.5%, 11.7%, 12.6%, 0.2%, and 2.5%, respectively. The prevalence of ATPO antibodies (odds ratio [OR]: 3.975; 95%; confidence interval [CI]: 3.085–5.122), ATG antibodies (OR: 3.759; 95% CI: 2.554–5.531), ANA (OR: 1.797, 95% CI: 1.182–2.731), AGPCA (OR: 2.503; 95% CI: 1.497–2.896), and anti-adrenal antibodies (OR: 9.808, 95% CI: 1.809–53.159) (Figure 2a–e) were significantly higher in vitiligo patients than in the control group. The routine screening of anti-thyroid antibodies should be performed in vitiligo patients to identify those at high risk of developing autoimmune thyroid disease.

UR - http://www.scopus.com/inward/record.url?scp=85049863699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049863699&partnerID=8YFLogxK

U2 - 10.1111/ddg.13574

DO - 10.1111/ddg.13574

M3 - 综述文章

AN - SCOPUS:85049863699

VL - 16

SP - 845

EP - 853

JO - JDDG - Journal of the German Society of Dermatology

JF - JDDG - Journal of the German Society of Dermatology

SN - 1610-0379

IS - 7

ER -